{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:40:40Z","timestamp":1771008040069,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Astellas Pharma Inc"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.jiac.2017.04.008","type":"journal-article","created":{"date-parts":[[2017,5,18]],"date-time":"2017-05-18T01:15:56Z","timestamp":1495070156000},"page":"724-726","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Antimicrobial activity of fidaxomicin against Clostridium difficile clinical isolates in Aichi area in Japan"],"prefix":"10.1016","volume":"23","author":[{"given":"Yuka","family":"Yamagishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Suematsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao","family":"Hagihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyomitsu","family":"Katsumata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshige","family":"Mikamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2017.04.008_bib1","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1086\/430315","article-title":"Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada","volume":"40","author":"Pepin","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2017.04.008_bib2","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa051590","article-title":"An epidemic, toxin gene-variant strain of Clostridium difficile","volume":"353","author":"McDonald","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jiac.2017.04.008_bib3","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1128\/AAC.48.6.2280-2282.2004","article-title":"In\u00a0vitro activity of OPT-80 against Clostridium difficile","volume":"48","author":"Ackermann","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.04.008_bib4","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1128\/AAC.48.12.4898-4902.2004","article-title":"In\u00a0vitro activities of OPT-80 and comparator drugs against intestinal bacteria","volume":"48","author":"Finegold","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.04.008_bib5","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1128\/AAC.00476-08","article-title":"In\u00a0vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile","volume":"52","author":"Karlowsky","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.04.008_bib6","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1128\/AAC.01623-06","article-title":"In\u00a0vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004","volume":"51","author":"Hecht","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.04.008_bib7","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1128\/AAC.48.11.4430-4434.2004","article-title":"Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species","volume":"48","author":"Credito","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.04.008_bib8","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jiac.2017.04.008_bib9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","article-title":"Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial","volume":"12","author":"Cornely","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiac.2017.04.008_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/2040622313511285","article-title":"Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance","volume":"5","author":"Mullane","year":"2014","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.jiac.2017.04.008_bib11","series-title":"Methods for antimicrobial susceptibility testing of anaerobic bacteria: approved standard-eighth edition M11\u2013A8 document","author":"CLSI","year":"2012"},{"key":"10.1016\/j.jiac.2017.04.008_bib12","series-title":"Performance standards for antimicrobial susceptibility testing: twenty-second informational supplement M100\u2013S22 document","author":"CLSI","year":"2012"},{"key":"10.1016\/j.jiac.2017.04.008_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1128\/jcm.29.1.33-37.1991","article-title":"Identification of toxigenic Clostridium difficile by the polymerase chain reaction","volume":"29","author":"Kato","year":"1991","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.jiac.2017.04.008_bib14","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1574-6968.2000.tb09122.x","article-title":"Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile","volume":"186","author":"Stubbs","year":"2000","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.jiac.2017.04.008_bib15","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1128\/AAC.35.6.1108","article-title":"In\u00a0vitro and in\u00a0vivo evaluation of tiacumicins B and C against Clostridium difficile","volume":"35","author":"Swanson","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.04.008_bib16","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1128\/AAC.00625-11","article-title":"Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection","volume":"55","author":"Goldstein","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.04.008_bib17","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.anaerobe.2009.09.005","article-title":"Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C.\u00a0difficile infection","volume":"15","author":"Citron","year":"2009","journal-title":"Anaerobe"},{"key":"10.1016\/j.jiac.2017.04.008_bib18","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1128\/AAC.00191-12","article-title":"Characterizations of clinical isolates of Clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan","volume":"56","author":"Liao","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.04.008_bib19","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1128\/AAC.00479-06","article-title":"In\u00a0vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Qu\u00e9bec, Canada","volume":"50","author":"Bourgault","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.04.008_bib20","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s10156-013-0553-5","article-title":"Antimicrobial susceptibilities of Clostridium difficile isolated in Japan","volume":"19","author":"Kunishima","year":"2013","journal-title":"J\u00a0Infect Chemother"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X17300934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X17300934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:56:38Z","timestamp":1761159398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X17300934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S1341321X17300934"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2017.04.008","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobial activity of fidaxomicin against Clostridium difficile clinical isolates in Aichi area in Japan","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2017.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}